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ABSTRACT
The Smg proteins Smg5, Smg6 and Smg7 are
involved in nonsense-mediated RNA decay (NMD)
in metazoans, but no orthologs have been found
in the budding yeast Saccharomyces cerevisiae.
Sequence alignments reveal that yeast Ebs1p is
similar in structure to the human Smg5-7, with
highest homology to Smg7. We demonstrate here
that Ebs1p is involved in NMD and behaves similarly
to human Smg proteins. Indeed, both loss and
overexpression of Ebs1p results in stabilization
of NMD targets. However, Ebs1-loss in yeast or
Smg7-depletion in human cells only partially
disrupts NMD and in the latter, Smg7-depletion
is partially compensated for by Smg6. Ebs1p
physically interacts with the NMD helicase Upf1p
and overexpressed Ebs1p leads to recruitment of
Upf1p into cytoplasmic P-bodies. Furthermore,
Ebs1p localizes to P-bodies upon glucose starvation
along with Upf1p. Overall our findings suggest that
NMD is more conserved in evolution than previously
thought, and that at least one of the Smg5-7
proteins is conserved in budding yeast.
INTRODUCTION
The cellular production of RNA is kept under surveillance
through elaborate quality control machineries able to
cope with errors that may occur during synthesis.
Mutations that give rise to premature termination
codons in mRNAs either due to mutations in DNA or
to errors that occur during transcription or pre-mRNA
splicing are handled at least in part by an intricate
RNA surveillance system named nonsense-mediated
RNA decay (NMD) (1). NMD detects and targets
‘nonsense’ mRNAs containing premature termination
codons (PTCs) for degradation, thereby preventing their
translation. Loss of functional NMD seems to have
diﬀerent consequences in diﬀerent organisms. Yeast and
worm NMD mutants as well as human cells siRNA-
depleted for the NMD factor Upf2 accumulate PTC-
containing mRNAs without apparent loss in viability
(2–6); on the contrary, impairment of NMD in ﬂies
leads to cell cycle arrest (7). In any case, one can speculate
that translation of PTC-containing transcripts could
lead to the production of truncated proteins with potential
deleterious eﬀects for the cell. It has been estimated
that approximately one-third of all human genetic
syndromes and many types of cancer arise from mRNAs
containing a PTC derived from mutations occurring in
the template gene. NMD might alleviate the severity of a
number of genetic disorders by decreasing the abundance
of disease-associated nonsense transcripts (8).
Upf1, Upf2 and Upf3 (for UP-Frameshift; also named
Smg2, Smg3 and Smg4, respectively for Suppressor with
Morphogenetic eﬀects on Genitalia) proteins play a
central role in NMD. They were ﬁrst discovered in
yeast as the result of a genetic screen looking for
mutations that suppressed an auxotrophic marker con-
taining a PTC stemming from a frameshift (5,6).
Successively, homologs of these three genes were also
found in other organisms including worms, ﬂies and
humans. Upf1 is a phosphoprotein with ATPase and 50–30
helicase activities (9–12). It is envisioned that the helicase
activity of Upf1 somehow allows the NMD surveillance
complex to scan RNA molecules. Consistently, ectopically
expressed helicase-dead variants of Upf1 exert a dominant
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negative eﬀect on NMD in diﬀerent organisms
(10,13). Upf2 and Upf3 proteins seem to interact with
Upf1 on the nonsense mRNA (14). Once the Upf complex
has recognized an mRNA as nonsense, this mRNA
is degraded via contributions from both the 50–30
decapping-dependent exonuclease pathway, and the dead-
enylation dependent 30–50 exosome pathway (15–17).
NMD most likely takes place in cytoplasmic foci
referred to as processing bodies (P-bodies) as many of
the proteins that are involved in decapping and general
RNA decay reside in P-bodies (18–20). Further supporting
this hypothesis, yeast PTC-containing mRNAs are
targeted to P-bodies in an Upf1p-dependent manner (14).
In higher eukaryotes including worms and mammals,
the core of the NMD machinery also comprises four
factors named Smg1, Smg5, Smg6 and Smg7. All these
factors inﬂuence the phosphorylation state of Upf1.
Smg1 belongs to the phosphoinositide 3-kinase-related
kinase (PIKK) family and directly phosphorylates Upf1 at
S/T-Q residues during NMD cycles (21). Although
Saccharomyces cerevisiae Upf1 has been recently demon-
strated to be a phosphoprotein (22), no obvious Smg1
ortholog has yet been identiﬁed in yeast. In contrary
to Smg1, the other Smg proteins (herein referred to as
Smg5-7) promote Upf1 dephosphorylation, which is likely
carried out by protein phosphatase 2A (PP2A) (4,23,24).
Consistently, Smg5-7 interact with PP2A and at the
same time directly bind to Upf1 through highly conserved
residues within their 14-3-3 domains (25). As is the
case for Smg1, no obvious Smg5-7 ortholog has been
found in S. cerevisiae, leading to the assumption that these
factors do not exist in yeast (1,26).
The S. cerevisiae Ebs1 protein was ﬁrst characterized
based on its sequence similarity with yeast Est1p, a
subunit of the telomerase holoenzyme, which adds newly
synthesized TG-rich repeats to the termini of yeast
chromosomes, the telomeres (27). Deletion of the EST1
gene leads to a continuous shortening of telomeres,
which ultimately causes loss of the telomeric cap and
cellular senescence (28). ebs1 cells also have short
telomeres compared to wild-type cells, however the
length of the telomeric tract is stable and cells do not
experience senescence (27). These observations suggest
that the telomere shortening phenotypes detected in est1
and in ebs1 cells stem from diﬀerent mechanisms.
More recently, it has been reported that Ebs1p
functions as a ‘global inhibitor of translation’ (29).
We and others have previously demonstrated that
the human genome contains three genes encoding for
polypeptides with sequence similarity to yeast Est1p and
Ebs1p. The three putative orthologs were named EST1A,
EST1B and EST1C (30,31). Similarly to yeast Est1p,
EST1A and EST1B interact with human telomerase.
Furthermore, overexpression of EST1A causes telomeric
dysfunctions (30,31). Strikingly EST1A, EST1B and
EST1C are identical to Smg6, Smg5 and Smg7, respec-
tively, raising the attractive possibility that Est1p and/or
Ebs1p might also function in NMD.
Here we demonstrate that EBS1 (but not EST1)
deletion leads to a slight but highly reproducible
stabilization of NMD targets. Moreover, Ebs1p possesses
several features typical of the Smg5-7 proteins: (i) Ebs1p,
as well as Upf1p, localizes to P-bodies upon glucose
starvation and (ii) overexpression of Ebs1p leads to
accumulation Upf1p in P-bodies. Altogether, we provide
evidence that Ebs1p is a new component of the yeast
NMD machinery and we propose that at least one of the
Smg5-7 proteins is conserved throughout evolution from
yeast to man. We also demonstrate that ebs1 mutants
and all the other tested NMD mutants are resistant to the
immunosuppressive drug rapamycin, implicating the
NMD machinery in cell growth control pathways.
MATERIALS AND METHODS
Antibodies
Rabbit anti-human Smg7 polyclonal antibody was
generated using a synthetic 40-amino acid long peptide
corresponding to a sequence close to the C-terminus of
Smg7 (N-PAMGGFGIDYLSATSSSESSWHQASTPSG
TWTGHGPSMED-C). Two rabbits were immunized
with the peptide at Eurogentec Bel S.A. (Belgium). The
peptide–antigen was coupled to NHS-activated Sepharose
4 Fast Flow (Pharmacia) and used to aﬃnity-purify anti-
Smg7 antibodies according to standard procedures.
Rabbit polyclonal anti-human Upf2, Upf3 and Smg6
were kind gifts from H.M. Jack, L. Maquat and
L. Harrington, respectively; goat polyclonal anti-human
Upf1 antibody (BL411G) was purchased from Bethyl
Laboratories; mouse monoclonal anti-Flag (M2) and anti-
human aTubulin (DM1A) antibodies were from Sigma;
rabbit polyclonal anti-myc (CM-100) was from Gramsch
Laboratories; mouse monoclonal anti-GFP (11814460001)
was from Roche; mouse monoclonal anti-HA.11
(MMS-101R-500) was from Covance; rabbit polyclonal
anti-human histone H3 (1791-100) was from Abcam.
Strain constructions and genetic manipulations
Yeast strains are described in Table 1. The genotypes
of the yeast strains are derived from either HFY1200
(32) (ade2-1, trp1-1, can1-100, leu2-3,112, his3-11,15,
ura3-1) or S288C (his31 leu20 met150 ura30). All
haploid strains in the S288C background were derived
from heterozygous diploids (Euroscarf deletion
consortium) and subsequently micromanipulated to
obtain the indicated haploid strain. Standard yeast
growth conditions and genetic manipulations were used
as described (33). Yeast transformations were performed
by the lithium acetate procedure (34). YBL108
(ebs1::EBS1-MYC13) was endogenously tagged using a
PCR-based method described previously (35). Strains
expressing endogenously tagged Upf1p-GFP and
Dcp2p-GFP were obtained from the Invitrogen GFP
clone collection. Ebs1p-dsRFP was endogenously tagged
using previously described methods (36). To construct
YBL79, the pMX6 NAT cassette was linearized with
EcoRI and transformed into YBL35. Transformants were
selected on YPD medium containing 100 mg/ml
nourseothricin.
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DNAmanipulations and plasmids
Standard procedures were used for recombinant DNA
manipulations (37). PCR was performed with the
High Fidelity polymerase kit as recommended by the
manufacturer (Roche) and veriﬁed by sequencing. Yeast
genomic DNA was prepared using the Wizard genomic
DNA puriﬁcation kit (Promega). Telomere PCR was
performed as previously described (38). Details of yeast
plasmid constructions i.e. pADH-HA-Ebs1 (pBL75) and
pADH-Smg7 are available upon request. All yeast
galactose overexpression plasmids were ordered from
Open-biosystems. The Est1-18myc plasmid was a kind
gift from V. Lundblad. The centromeric DCP2-RFP
plasmid (pTG003) was a kind gift from Mark Schmitt.
The human Smg7 cDNA was obtained from the
Kazusa DNA research Institute (clone KIAA0250). The
Flag-Smg7 plasmid encodes for a N-terminally tagged
Smg7 variant cloned under the control of the CMV
promoter.
Immunoprecipitations and western blots
Yeast cultures measuring 50ml were grown until mid-log
phase, centrifuged washed in 10ml of ice-cold PBS 1 and
re-centrifuged. Cell pellets were resuspended in 200 ml of
IP buﬀer (50mM Tris pH 7.5, 150mM NaCl, 5mM
MgCl2, 2% NP-40, protease inhibitor cocktail from
Roche) and broken 2 20 s using the Bio101 disruptor.
A total of 800 ml of IP buﬀer was then added and lysates
were centrifuged at 13 000 r.p.m. for 10min at 48C.
For IPs, 3 ml of polyclonal anti-myc antibody was added
to 1mg of cell lysate and gently mixed at 48C for 2 h in
the presence of 30 U of DNase I (Roche). Fifty microliters
of pre-washed protein G beads were added and mixed
for 2 h. Beads were washed 5 5min and immunocom-
plexes were eluted in 50 ml of 3 Laemmli buﬀer.
For human cells, protein extractions and IP conditions
were previously described (3). Western blot experiments
were performed according to standard procedures.
RNA isolation and northern blotting
For RNA isolation from yeast, cells were grown in
10ml of medium until approximately OD600 0.35.
For RNA half-life experiments, thiolutin (Biotrend
GmbH) was directly added to the culture medium to a
ﬁnal concentration of 3 mg/ml. Cells were then harvested
and treated with Zymolyase for 30min at 308C in order to
produce spheroblasts. Human and yeast RNA was
isolated using the RNeasy mini-kit from Qiagen. For
northern blots, 5–20 mg of RNA was loaded onto
formaldehyde agarose gels, separated by electrophoresis
and transferred to Hybond N+ membranes (Amersham).
Blots were blocked in Church buﬀer for 1 h at 608C and
then incubated with 32P-labeled DNA probes.
Hybridizations were performed for 18 h at 50–608C and
washes were in 0.2SSC, 0.5% SDS at 50–608. Signals
were detected and quantiﬁed with a phosphoimager (Fuji)
and the AIDA software (Raytest). The b-globin probe is a
PCR fragment corresponding to exon 1 of the human
gene; the human b-actin probe and the yeast 7S probe are
50 end-labeled oligonucleotide (b-actin: 50-GTGAGGA
TCTTCATGAGGTAGTCAGTCAGGT-30; 50-GTCTA
GCCGCGAGGAAGG-30); the CYH2 and the ade2-1
probe are DNA fragments prepared from the pGEM4Z-
CYH2 plasmid and an xrn1: ADE2 disruption plasmid,
respectively (kind gifts of A. Jacobson); the URA5 and
STE2 probes are PCR products of the entire ORFs and
RP51B pre-mRNA is a PCR fragment of the intron.
Fluorescence microscopy
Yeast cells were washed twice with complete minimal
medium and resuspended in the same. Cell suspensions
were spotted onto clean slides and rapidly observed.
Images were acquired using the LSM510 confocal micro-
scope (Zeiss) equipped with Argon (wavelengths 457/488/
514) and HeNe (wavelength 543) lasers.
Short hairpin (ShRNA)-mediated depletionofhumanproteins
ShRNA plasmids were generated as described previously
(3) using a variant of the pSUPER plasmid containing the
puromycin-resistance gene. The 19 nt target sequences
were as follows. For human Upf1: 50-GAGAATCGC
CTACTTCACT-30 (shUpf1); for human Smg6: 50-GGGT
CACAGTGCTGAAGTA-30 (sh6); for human Smg7: 50-G
TATTAGTGCGACACCACT-30 (sh7A) and 50-CGCTTG
ATCTCTTATTAGGCA-30 (sh7B). HeLa cell lines with a
stably integrated PTC-containing human b-globin repor-
ter gene (HeLa b-globinNS39) or the wild-type b-globin
Table 1. Yeast strains used in this work
Strain Genotype Background Source
HFY1200 Mat a HFY (32)
HFY870 Mat a upf1::HIS3 HFY (32)
YCA1 Mat a ebs1::TRP1 HFY This study
YCA2 Mat a est1::HIS3 HFY This study
YCA3 Mat a ebs1::TRP1
est1::HIS3
HFY This study
YBL40 Mat a S288c This study
YBL35 Mat a ebs1::KAN S288c This study
YBL38 Mat a upf1::KAN S288c This study
YBL89 Mat a upf1::NAT
upf1::KAN
S288c This study
YBL125 Mat a Ebs1-RFP
URA3 Upf1-GFP
HIS3
S288c This study
YBL130 Mat a Ebs1-RFP
URA3 Dcp2-GFP
HIS3
S288c This study
YBL11 Mat a Upf1-GFP HIS3 S288c This study
YBL102 Mat a ebs1::NAT xrn1::NAT S288c This study
YBL107 Mat alpha ebs1::EBS1-13-myc
KAN Upf1-GFP HIS3
S288c This study
YBL87 Mat a ski2::KAN S288c This study
YBL99 Mat a ski2::KAN ebs1::NAT S288c This study
YBL43 Mat a xrn1::KAN S288c This study
YBL59 Mat a upf2::KAN S288c This study
YBL47 Mat a upf3::KAN S288c This study
YBL54 Mat a lsm1::KAN S288c This study
YBL45 Mat a lsm7::KAN S288c This study
YBL56 Mat a pat1::KAN S288c This study
YBL50 Mat a dhh1::KAN S288c This study
YBL79 Mat a ebs1::NAT S288c This study
YBL108 Mat a ebs1::EBS1-13-myc KAN S288c This study
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gene (HeLa b-globinWT) were a kind gift from
O. Mu¨hlemann. A total of 5 105 cells were plated onto
30mm dishes, grown for 15 h and transfected with 4–8 mg
of plasmid DNA using the Lipofectamine 2000 reagent
(Invitrogen). Twenty-four hours after transfection, cells
were selected in medium containing 1.5 mg/ml puromycin
(Fluka) until the mock-transfected cells were dead
(1–2 days).
35S incorporation following rapamycin treatment
Yeast cultures measuring 10ml were grown to logarithmic
phase in SD medium lacking methionine. Rapamycin was
added to a ﬁnal concentration of 100 nM. Rapamycin
treatment was for 45min preceding the addition of labeled
methionine. Cells were pelleted, and resuspended in 1 l of
the same medium, followed by 10min labeling with 7 mCi
of [35S]methionine (Amersham). Incorporation was
stopped by addition of cycloheximide (100 mg/ml,
Sigma), followed by cell-lysis and TCA precipitation of
proteins. Equal amounts of proteins were loaded on a
polyacrylamide gels, and analyzed by SDS–PAGE,
CoomassieR (Acros Organics) staining and autoradiogra-
phy. Staining intensities were measured by an Imaging
Densiometer (Bio-rad) and quantiﬁed by using the
QuantityOne software (Bio-rad). Dried gels were exposed
to a phosphoscreen for 4 h and analyzed using a
phosphoimager (Storm 860, Amersham) and the ImageJ
software (http://rsb.info.nih.gov/ij/).
Polysome analysis
Yeast cultures (200ml) were grown to exponential
phase. Rapamycin-treated samples were grown in
100 nM rapamycin for 30min. All cultures were treated
with 100 mg/ml cycloheximide for 10min on ice. After
centrifugation, pellets were washed twice and resuspended
in 700 ml lysis buﬀer (10mM Tris–HCl pH 7.5, 100mM
NaCl, 30mM MgCl2, 100 mg/ml cycloheximide, 0.2mg/ml
heparin, 0.2ml/ml DEPC). Subsequently cells were lyzed
by bead beating. Extracts [8 absorption units at 260 nm
(A260)] were loaded on 12.2ml 15–50% linear sucrose
gradients prepared in 50mM Tris–acetate pH 7.5, 50mM
NH4Cl, 12mM MgCl2). The gradients were centrifuged
at 39 000 r.p.m. in a Beckman SW41 rotor at 48C for
2 h 45min followed by analysis with an ISCO UV-6
gradient collector.
RESULTS AND DISCUSSION
Sequence analysis of the Est1/Ebs1/Smg5-7 protein family
Yeast Ebs1p and Est1p are paralogous proteins that share
27% sequence identity and 48% sequence similarity.
Whereas Ebs1p has been implicated in both telomere
length regulation (27) and translation inhibition (29), the
only proposed role of Est1p is to promote the recruitment
of telomerase to chromosome ends (39). Interestingly, the
N-terminal regions of both Ebs1p and Est1p comprise a
14-3-3 domain that is highly similar to that found in the
higher eukaryotic NMD proteins Smg5, Smg6 and Smg7
(25). The putative 14-3-3 domain of the human Smg
proteins forms a classic phosphoserine-binding
pocket, which was shown to interact with phosphorylated
Upf1 (25). We generated a multiple sequence alignment
of the 14-3-3 domains of the human Smg proteins and
the N-terminal region of both Ebs1p and Est1p
(Figure 1). Careful inspection of the 14-3-3 sequences
of Ebs1p and Est1p revealed diﬀerences between the
two proteins with respect to key residues implicated
in phosphoserine binding (40), suggesting diﬀerent
binding speciﬁcities. The human 14-3-3 zeta isoform
(HZI) (40) residue Tyr128 is conserved in both Est1p
and Ebs1p. HZI Asn173 is not conserved in either of
the two yeast proteins while conservation is maintained
in the human Smg proteins (Figure 1). Finally, HZI Lys49,
Arg56 and Arg127 are conserved in Ebs1p and
the other Smg proteins but not in Est1p (Figure 1).
Figure 1. The Smg5-7 14-3-3 phosphoserine-binding residues are
conserved in Ebs1p. Multiple sequence alignment of the 14-3-3
domains of human Smg5 (amino acids 19–266), Smg6 (576–818) and
Smg7 (1–236) proteins with the N-terminal regions of yeast Ebs1
(23–291) and Est1 (22–291) proteins. The alignment was produced
using the ClustalW program. Alpha helices 1–9 (a1–a9) are shown.
Conserved amino acids are indicated as white letters on a black
background while similar amino acids are white letters on a gray
background. Arrowheads point to consensus 14-3-3 residues
(indicated below each arrowhead) derived from the human 14-3-3
zeta isoform that have been implicated in phosphoserine binding for
14-3-3 domains across species. Black arrowheads indicate 14-3-3
residues that are conserved with respect to side-chain charge content
in Ebs1p but not in Est1p, the white arrowhead points to a residue
conserved in both Ebs1p and Est1p, the gray arrowhead highlights
a residue, which is not conserved in either of the two yeast proteins.
The cartoon depicts the domain architecture of yeast Ebs1 and
human Smg7 proteins. Two conserved regions named CR1 and
CR2 are indicated as black boxes and their sequence is shown in
the lower insets. CR1: amino acids 231–283 in Ebs1p and 174–226
in Smg7; CR2: amino acids 710–789 in Ebs1p and 933–1013 in Smg7.
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Pairwise alignments of Ebs1p with each of the three
human Smg5-7 proteins revealed that yeast Ebs1p and
human Smg7 have two highly conserved regions that do
not exist in either Smg5 or Smg6. We have named these
regions conserved region 1 (CR1) and conserved region 2
(CR2) (Figure 1, see insets). Furthermore, while both
Smg5 and Smg6 have C-terminal PilT-amino-terminal
(PIN) domains, a domain often associated with nuclease
activity, (26,30,41,42), Smg7 does not contain a PIN
domain, as is the case for both Est1p and Ebs1p. This
sequence analysis suggests that Ebs1p has a domain
organization similar to human Smg7 and further predicts
that Ebs1p and/or Est1p may play a role in NMD as do
the Smg proteins.
Deletion of EBS1 but not EST1 results in NMD
defects similar to Smg depletion
To determine if Ebs1p and/or Est1p are involved in
NMD, we deleted the complete EBS1 and EST1 ORFs
and determined if the two well-characterized NMD targets
CYH2 pre-mRNA and a PTC containing ade2-1 allele
were stabilized. While deletion of the EST1 gene did not
lead to stabilization of the analyzed NMD target mRNAs,
ebs1 cells showed a slight but very consistent accumula-
tion of both CYH2 pre-mRNA and ade2-1 mRNA
[1.52 0.12 (n=3) fold increase for ade2-1 and
1.78 0.23 (n=5) fold increase for CYH2] (Figure 2A
and B). Moreover, est1 ebs1 double mutants did not
show increased stabilization levels above that of the ebs1
single mutant, indicating that Est1p is not able to
compensate for Ebs1p depletion (Figure 2A). The fact
that the stabilization of the NMD targets in ebs1 cells
was lower than the one observed in upf1, upf2 and
upf3 cells (Figure 2A and B and data not shown)
suggests that Ebs1p plays a non-essential role in canonical
NMD, explaining why EBS1 was not found in the UPF
screen which identiﬁed UPF1, UPF2 and UPF3 (5,6).
In order to directly measure the stability of NMD
targets, we treated wt and ebs1 cells with the transcrip-
tion inhibitor thiolutin (43) and measured the relative
amounts of CYH2 pre-mRNA and mRNA, as well as the
pre-mRNA of another NMD target, RP51B at diﬀerent
times after addition of the inhibitor. In our experimental
settings, the half-life (t1/2) of the CYH2 pre-mRNA was
2.7min in ebs1 cells, while it was 1.2min in wild-type
cells (Supplementary Figure S1). Similarly, the t1/2 of
RP51B pre mRNA was 6.5min in ebs1 cells, while it
was 3.3min in wild-type cells. On the contrary, the t1/2 of
the short-lived non-NMD targets URA5 (Wt t1/2 8.6min,
ebs1 t1/2 7.8min) and STE2 (Wt t1/2 8.4min, ebs1 t1/2
7min) were not stabilized in ebs cells (Supplementary
Figure S1). These observations suggest that EBS1 deletion
speciﬁcally impairs with the degradation of NMD targets.
We then generated ebs1 upf1 double mutants and
found that there was not a synergistic or an obvious
additive eﬀect with regards to CYH2 pre-mRNA stabili-
zation (Figure 2B), suggesting that EBS1 lies in the same
genetic pathway as the rest of the canonical genes involved
in NMD.
Similar to the conservative eﬀects on NMD, we noticed
that the short telomere phenotype of ebs1 cells (27) is
also less severe than that seen in upf1 cells
(Supplementary Figure S2). This is consistent with the
proposed model that the short telomere defect in upf
mutants is an indirect eﬀect of incomplete NMD (44).
Nonetheless, we have recently shown that mammalian
SMG proteins localize to telomeres and promote dissocia-
tion of telomeric repeat containing RNA (TERRA) from
telomeres (45). It is possible that TERRA is also
conserved in yeast and that the telomere shortening
observed in yeast NMD mutants could derive at least in
part from loss of proper TERRA regulation at chromo-
some ends.
To analyze the consequences of depletion of Ebs1-
related human factors, we generated shRNAs directed
against human Smg6 or Smg7. ShRNAs were validated by
western blots, which conﬁrmed that the levels of targeted
Figure 2. Ebs1 participates in NMD in a way similar to human Smg
proteins. (A and B) Total RNA from log phase yeast grown in YPD
was prepared from wt, upf1, ebs1, est1, ebs1est1 and
ebs1upf1 cells and subjected to northern blot analysis using
a probe which detects both the CYH2 pre-mRNA and CYH2
mRNA. In (A) the ﬁlter was stripped and re-probed to detect the
ade2-1 mRNA. CYH2 pre-mRNA levels (CYH2 ratio) and ade2-1
mRNA levels (ade2-1 ratio) are expressed relative to wild-type cells,
after normalization using the CYH2 mRNA signal. (C) HeLabGWT
and HeLabGNS39 cells (see Materials and Methods section) were
transfected with shRNA vectors against human Smg7 (sh7A and sh7B),
human Smg6 (sh6) and human Upf1 and with empty vector controls
(shEV). Five days after transfection, total mRNA was prepared and the
levels of b-globin mRNA were determined on a northern blot.
Alternatively, the same cell lines were transfected with vectors
expressing a Flag-tagged version of human Smg7 (F-Smg7) or empty
vector controls (F-EV) and processed 48 h after transfection. The signal
of bGNS39 (bGL ratio) is expressed relative to empty vector-transfected
cells, after normalization using the actin signal (loading control) and
the signal of bGWT. (D) Wild-type yeasts were transformed with
centromeric plasmids harboring EBS1 and Smg7 under the constitutive
ADH promoter, or with empty vector alone. Total RNA was probed
using the CYH2 probe as in A–C.
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proteins were strongly decreased (Supplementary
Figure S3). As previously documented (26), shRNA-
mediated depletion of Smg6 and Smg7 induced stabiliza-
tion of a PTC containing b-globin mRNA (bGLNS39)
when compared to empty vector transfected cells
(Figure 2C). Remarkably, as is the case for yeast ebs1
mutants, knockdown of Smg7 did not stabilize bGLNS39
mRNA to the extent achieved using shRNA against
human Upf1. However, simultaneous shRNA-mediated
depletion of Smg6 and Smg7 resulted in a dramatic
increase in bGLNS39 transcript that was comparable to the
one observed in cells depleted for Upf1 (Figure 2C).
Similar results were obtained using diﬀerent shRNA-
directed against Smg7, Smg6 and Upf1 (Figure 2C and
data not shown). This suggests that the human Smg6 and
Smg7 proteins can substitute for each other and raises the
possibility that there may be another Smg-like protein in
yeast (which is not Est1p), that can partially substitute for
Ebs1p. We searched the yeast database for PIN domain
containing proteins, which could be potential orthologs of
either Smg5 or Smg6, and identiﬁed NMD4, YKR096w
and YOR166c. Analysis of NMD targets in the three
single mutant strains as well as in the double mutants with
ebs1 did not reveal any increase in NMD impairment as
compared to single EBS1 mutants (data not shown),
ruling out the possibility that these PIN-domain-contain-
ing proteins could substitute for Ebs1p.
We then tested if overexpressing either human Smg7 or
yeast Ebs1 proteins could aﬀect NMD. Indeed, over-
expression of Smg7 in human cells resulted in stabilization
of bGLNS39 (Figure 2C, compare last two lanes).
Similarly, overexpression of both Ebs1 and Smg7 in
yeast resulted in slight stabilization of the CYH2 pre-
mRNA (Figure 2D). Because Smg7 participates in the
dephosphorylation of Upf1, it is possible that the
impairment of NMD function observed in human cells
depleted for or overexpressing Smg7 derives from a
compromised balance between phosphorylated and
unphosphorylated Upf1. Although yeast Upf1p has
recently been demonstrated to be a phosphoprotein (22),
we were unsuccessful in our attempts to detect phos-
phorylated Upf1p. Furthermore, there is no evidence that
phosphorylation of yeast Upf1p plays a role in NMD and
the human PI3-like Upf1 kinase, Smg1, has no apparent
functional homolog in yeast. Indeed, deletion of the
known yeast PI3-like kinases tor1, tel1 or mec1 does not
impair with NMD function (data not shown).
ebs1 cells are competent to inhibit global translation upon
rapamycin treatment
Slightly increased steady-state levels of NMD targets in
EBS1 cells were already reported by Ford and collea-
gues (29). The same study also demonstrates that ebs1
deletion leads to increased translation of a lacZ reporter
gene, while overexpression of Ebs1p leads to decreased
translation of the same reporter. Furthermore, yeast
strains deleted for EBS1 display resistance to the
immunosuppressive drug and inhibitor of the TOR
kinase, rapamycin (29). These observations led the authors
to propose that Ebs1p might work as a global translation
inhibitor and that the NMD defects as well as the
rapamycin resistance observed in ebs1 cells are due to
a failure in proper translation regulation (29).
To verify the involvement of Ebs1p in processes of
translation inhibition, we performed pulse-labeling experi-
ments with 35S-labeled methionine following rapamycin
addition, which is known to result in down-regulation of
translation (46). We found that 35S incorporation was
inhibited to similar extents in wild-type and ebs1 cells
following rapamycin treatment (Supplementary
Figure S4). We also analyzed polysome proﬁles of wild-
type and ebs1 cells following either rapamycin addition
or glucose starvation and consistently we noticed the
accumulation of an 80S monosome peak in both samples
(Supplementary Figure S4). On the contrary, the rapamy-
cin insensitive fpr1 cells showed no noticeable proﬁle
diﬀerence from the untreated control culture following
the addition of rapamycin (Supplementary Figure S4).
Similarly, polysome proﬁles from cells overexpressing
Ebs1p did not show any substantial diﬀerence as
compared to cells transformed with empty vector controls
(Supplementary Figure S4). We then asked if Ebs1p level
alterations could aﬀect the cellular sensitivity to diﬀerent
translational inhibitors, including cycloheximide, para-
momycin and hygromycin B. Neither the deletion nor the
overexpression of Ebs1 aﬀected the sensitivity of the cells
to the tested inhibitors (Supplementary Figure S5). We
thus conclude that the NMD defect and the rapamycin
resistance observed in ebs1 cells are not a consequence of
a general lack of translation inhibition. The apparent
discrepancy between the data reported here and the ones
shown by Ford et al. (29) might be due to the diﬀerent
experimental settings used to monitor translation
eﬃciency.
We also noticed that all tested deletion mutants
involved in NMD (upf1, upf2, upf3 and xrn1)
were highly resistant to rapamycin (Supplementary
Figure S5). Furthermore, upf1 ebs1 double mutant
cells had a rapamycin resistance that was similar to the
respective single mutants, suggesting that both factors
may function in the same genetic pathway that determines
rapamycin sensitivity (Supplementary Figure S5). The
rapamycin resistance of upf1 and ebs1 cells does not
exactly recapitulate the defects of the respective mutants in
NMD, which are much more pronounced upon UPF1
deletion. The even more pronounced rapamycin resistance
of upf2 and upf3 cells, which behave identical to upf1
with regard to NMD-dysfunction, combined with the fact
that ebs1 xrn1 and upf1 xrn1 double mutants are
additive in terms of rapamycin resistance may suggest
additional NMD-independent regulatory roles for these
proteins (Supplementary Figure S5). In this regard, it is
interesting to note that yeast Upf1p has been implicated in
the traﬃcking of normal mRNAs in and possibly out of
P-bodies while Upf2 and Upf3 work further downstream,
and only on PTC-containing RNAs (14). It will be
interesting to examine if Ebs1p and Upf1p collaborate in
traﬃcking of normal mRNAs or yet another regulatory
circuit that may explain the diﬀerent extent of rapamycin
resistance.
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Ebs1p localizes to P-bodies and interacts with Upf1p
Processing bodies or P-bodies house all of the decapping
proteins, such as Dcp1p, Dcp2p and the Lsm proteins, as
well as the main 5’ exonuclease, Xrn1p (47,48). It is
predicated that the majority of RNA degradation occurs
within P-bodies and it has been demonstrated that yeast
NMD substrates are also targeted in an Upf1p-dependent
manner to the P-bodies (14). In yeast, Upf1p itself has
been detected within P-bodies upon depletion of the
decapping enzymes or XRN1, which results in RNA
accumulation within P-bodies and hence increased P-body
size due to the accumulation of incompletely processed
RNAs (14). Yeast Upf1p can also be seen in P-bodies in
upf2 and upf3 mutants where Upf2p and Upf3p also
trigger nonsense mRNA decapping in wild-type cells (14).
Glucose starvation has also been shown to increase
P-body size as judged by scoring the size of Dcp2p-
GFP-containing foci (49).
We constructed a dsRED-tagged version of Ebs1p and
noticed a diﬀuse cytoplasmic staining in log phase cells
grown in rich medium. Upon glucose starvation, Ebs1p-
dsRED formed discrete cytoplasmic foci that co-localize
with Dcp2p-GFP, indicating that like Upf1p, Ebs1p
can localize to P-bodies (Figure 3). Furthermore,
we found that Upf1p-GFP also co-localizes with Ebs1p-
dsRED upon glucose starvation (Figure 3). While both
Dcp2-GFP and Upf1-GFP protein levels were diminished
upon glucose starvation (Supplementary Figure S6),
we noticed that Ebs1p levels were not strongly aﬀected
(Supplementary Figure S6, see below). In contrary to
Upf1p, only a fraction of Ebs1p-dsRED is recruited
to P-bodies upon glucose starvation, with a substantial
fraction remaining diﬀuse in the cytoplasm. This
observation suggests that the P-body-associated function
of Ebs1p does not require the entire cellular reservoir of
Ebs1p.
Overexpression of Smg5 and Smg7 in human cells
results in the accumulation of Upf1 into P-bodies, while
overexpression of Smg6 forces Upf1 into foci that do not
co-localize with markers for P-bodies (50). Therefore,
we overexpressed Ebs1p under the control of the ADH
promoter and found that analogous to human Smg5 and
7, this also resulted in the recruitment of Upf1p-GFP into
cytoplasmic foci containing an RFP-tagged version of
Dcp2p (Figure 4). Importantly, overexpression of Ebs1p
induces accumulation of UPF1-GFP protein as measured
by western blotting experiments (Supplementary
Figure S3). Because overexpression of Upf1p can increase
the levels of Upf1p itself in P-bodies (14), we cannot
exclude that the Upf1-containing P-bodies that we observe
in cells overexpressing Ebs1p may at least in part derive
from the higher intracellular levels of Upf1p. Nevertheless,
co-immunoprecipitation experiments of endogenously
expressed proteins show that Ebs1p-13myc (but not
Est1p-18myc; data not shown) co-immunoprecipitates
together with Upf1p-GFP (Figure 5A), suggesting that
Ebs1p might directly interact with Upf1p in P-bodies.
The amount of Upf1p that co-immunoprecipitated with
Ebs1p did not increase following glucose withdrawal
(Supplementary Figure 6), suggesting that glucose
starvation leads to the recruitment of pre-associated
Ebs1p-Upf1p molecules into P-bodies. Interestingly, the
interaction between Upf1p and Ebs1p was maintained
when extracts were treated with RNase prior to perform-
ing the immunoprecipitation experiments (Figure 5A).
This is in partial contrast to what we observed in human
cells, whereby endogenous Upf1 co-immunoprecipitates
Smg7 in a partially RNA-dependent manner (Figure 5B).
We speculate that the interaction between Upf1p/Upf1
and Ebs1p/Smg7 may occur through direct protein–
protein interactions and in human cells also through
RNA molecules simultaneously bound to both factors.
The interaction of human Upf1 with human Upf2 and
Upf3 is also partially lost when extracts are treated with
RNase (Figure 5B), suggesting that RNA molecules
stabilize the entire human NMD core complex.
The above-described results suggest that Ebs1p could
potentially be involved in either promoting Upf1p delivery
or Upf1p retention in P-bodies, drawing another
Figure 3. Ebs1p and Upf1p co-localize in P-bodies in glucose-starved cells. Yeast cells expressing Ebs1p-dsRED and Dcp2p-GFP fusions as well as
cells expressing Ebs1p-dsRED and Upf1p-GFP were grown in rich synthetic media and successively resuspended in media lacking glucose while
shaking at 308C. Four hours after, confocal images of live cells were taken. Arrows point to cytoplasmic foci where a co-localization between Ebs1p-
dsRED with Dcp2p-GFP and Ebs1p-dsRED with Upf1p-GFP occurred. Scale bar represents 2.5 mm.
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parallel between the Smg5-7 proteins and Ebs1p. In fact,
the C-terminal region of the human Smg7 polypeptide is
suﬃcient for recruiting Upf1 into P-bodies when over-
expressed (50). The CR2 present in the C-terminus of both
Smg7 and Ebs1 (Figure 1) might represent a structural
domain essential for the Ebs1-induced localization of
Upf1p into P-bodies. However, Upf1p-GFP is still
eﬃciently recruited into cytoplasmic foci upon glucose
starvation in ebs1 cells (data not shown), indicating that
Ebs1p alone is not required for the Upf1p recruitment into
P-bodies but possibly for downstream regulatory events,
which may include Upf1p retention or release. We cannot,
however, rule out the possibility that there is another
protein substituting for Ebs1p in its absence, which would
allow Upf1p recruitment. This second hypothesis is
consistent with the fact that NMD target accumulation
is incomplete in single deletion of EBS1 as well as in single
knockdowns of Smg6 and Smg7 (Figure 2).
In conclusion, our data indicate that Ebs1p is a novel
member of the NMD machinery in yeast and a putative
ortholog of human Smg7. Thus, although it has been
assumed previously that Smg proteins do not exist in
yeast, our data suggest that careful screening of the yeast
genome may allow identiﬁcation of additional Smg-like
proteins, which would further corroborate conservation of
NMD throughout eukaryotes.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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